Unfortunately, in recent years, there has been an increase in cases of breast cancer detected in women. Even if the tumor is found at an early stage and successfully removed, there remains a risk of recurrence, and to rule out a second cancer, the patient undergoes a course of hormone therapy. However, no hormone therapy provides a 100% guarantee. On the other hand, even the most advanced hormone therapy is a serious challenge for the body.
How can one know if there is a risk of recurrence after the removal of a breast tumor?
Recently, Israel has begun using the latest molecular biology test Prosigna, which provides the most accurate answers to these questions with a guarantee of over 10 years. This test is much more reliable than all currently available methods of molecular biological diagnostics. Specialists at the Top Ichilov clinic conduct the Prosigna test at the highest level, using the most modern equipment and in just a few days.
Only the Prosigna test combines the study of the genetic profile, tumor size, and the level of spread of cancer cells.
Send your records — an Ichilov physician will reply within 1–2 days, free of charge.
Prosigna – a guarantee of accurate results
The method is approved by the U.S. Food and Drug Administration (FDA) and European healthcare quality control bodies, and its high effectiveness and reliability have been proven by numerous clinical trials.
Who is the Prosigna test performed for?
The test is conducted for patients who have had an early-stage breast tumor removed and who are postmenopausal, with estrogen and progesterone receptors (ER, PR), that is, with hormone-dependent cancer.
How does the Prosigna test work?
This is the only test in the world that helps to express the risk of breast cancer recurrence with high accuracy in percentage terms, with a guarantee of over 10 years. The test studies 50 genes (PAM50 profile). Depending on the percentage risk, patients are divided into 3 groups: low, medium, and high risk. The test examines 4 molecular subtypes of breast cancer: Luminal A, Luminal B, Basal-Like, and HER2 Enriched. Thus, the test considers all aspects of tumor biology, allowing for accurate conclusions about the type of desired treatment and the possibility of recurrence.
The oncologist provides a referral for the test, and the material for it is a fragment of the tumor tissue removed during surgery. Testing takes only a few days and is conducted using the innovative nCounter device developed by the renowned company Nanostring Technologies.
- Breast cancer